Tag: Tardive dyskinesia

According to one study, up to 2.4% of patients exposed to certain medications can experience a life-threatening, drug-induced movement condition called neuroleptic malignant syndrome. Understanding what is drug-induced movement—abnormal, involuntary motions caused by a medication—is crucial for patient safety and effective treatment.

Affecting an estimated 500,000 people in the U.S., tardive dyskinesia (TD) is a significant concern [1.9.2]. This raises the critical question for many patients and clinicians: **Does gabapentin cause tardive dyskinesia?** While not a classic trigger, the answer is nuanced.

According to the National Institutes of Health, extrapyramidal symptoms (EPS) are a common side effect of antipsychotic medications, with prevalence estimates ranging significantly based on the specific drug used and patient population. This guide explains what are the four extrapyramidal symptoms, their characteristics, and how they relate to pharmacotherapy.

According to one study, up to 25% of adult patients using risperidone can experience movement-related side effects. Yes, risperidone can cause mobility issues through various mechanisms, which can affect balance, movement control, and stability. These effects can range from temporary and minor to severe and persistent, with elderly patients and those on higher doses being at particular risk.

In chronic psychiatric patient populations, the prevalence of drug-induced parkinsonism, a condition marked by muscle stiffness, can range from 17% to 72% [1.3.1]. Yes, **can antipsychotics cause muscle stiffness** is a significant concern, primarily through a group of side effects known as extrapyramidal symptoms (EPS) [1.2.1, 1.2.3].

Clinical trials have shown that aripiprazole (Abilify) can cause tremors, with one long-term study reporting an incidence of 8% compared to 2% with a placebo. Understanding the likelihood and nature of this movement disorder is crucial for those asking, 'Does Abilify cause tremors?' and their healthcare providers. This side effect, while often mild, is related to the drug's effect on dopamine receptors and warrants proper management if it occurs.

According to FDA boxed warnings, elderly patients with dementia-related psychosis who are treated with antipsychotic drugs like prochlorperazine are at an increased risk of death. This serious risk, along with other severe adverse effects, solidifies why prochlorperazine is considered a high-risk medication, especially for vulnerable populations and when used long-term.

In 2020, over 600,000 prescriptions for prochlorperazine were issued in the United States [1.3.3]. The answer to **'Does prochlorperazine affect dopamine?'** is a definitive yes; its primary mechanism of action involves blocking dopamine receptors in the brain, which is key to both its therapeutic effects and its potential side effects [1.2.1, 1.3.3].

Tardive dyskinesia (TD) is a debilitating movement disorder most commonly associated with long-term use of dopamine-blocking agents like certain antipsychotics and the gastrointestinal drug metoclopramide. This article investigates whether the prokinetic medication, prucalopride, poses a similar risk for causing tardive dyskinesia.

First approved by the FDA in 2017 for tardive dyskinesia, Ingrezza was the first medication developed specifically for this condition. This makes many wonder: What type of med is Ingrezza? It is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, a class of drugs that regulates dopamine signaling in the brain.